Skip to main content
main-content

Spondyloarthropathies

Ankylosing spondylitis

Immunogenicity of influenza vaccine confirmed in patients with rheumatic disease

Influenza vaccination gives rise to an adequate immune response among patients with rheumatic conditions, researchers report.

25-02-2019 | Vaccination | Highlight | News

Immunogenicity of influenza vaccine confirmed in patients with rheumatic disease

Influenza vaccination gives rise to an adequate immune response among patients with rheumatic conditions, researchers report.

Trials of JAK inhibitors in spondyloarthritis: A round-up

medwireNews rounds up the completed and ongoing clinical trials investigating JAK inhibitors in patients with spondyloarthritis.

21-02-2019 | Spondyloarthropathies | Feature | Article

Trials of JAK inhibitors in spondyloarthritis: A round-up

medwireNews rounds up the completed and ongoing clinical trials investigating JAK inhibitors in patients with spondyloarthritis.

13-02-2019 | Ankylosing spondylitis | News

VTE risk elevated in patients with ankylosing spondylitis

Patients with ankylosing spondylitis have a significantly increased risk for venous thromboembolism compared with the general population, with the risk apparently highest in the first year after diagnosis, study findings indicate.

30-01-2019 | Axial spondyloarthritis | News

Elevated fecal calprotectin linked to worse disease activity in axSpA

Elevated levels of fecal calprotectin, an indicator of gut inflammation, are associated with increased disease activity and reduced physical function in patients with axial spondyloarthritis, research shows.

29-01-2019 | Secukinumab | News

IBD ‘uncommon’ in patients treated with secukinumab

Inflammatory bowel disease is an “uncommon” occurrence among patients with psoriatic arthritis, ankylosing spondylitis, or psoriasis who are treated with the interleukin-17A inhibitor secukinumab, researchers report.

21-01-2019 | Ankylosing spondylitis | News

Trial results back TNF inhibitor dose-reduction strategy in ankylosing spondylitis patients

A dose-reduction strategy may be feasible for ankylosing spondylitis patients in sustained clinical remission with tumor necrosis factor inhibitor treatment, findings from the open-label REDES-TNF trial suggest.

04-12-2018 | Ankylosing spondylitis | News

Elevated CRP levels may point to better secukinumab response in AS patients

Ankylosing spondylitis patients with elevated C-reactive protein levels may experience greater benefits from treatment with the interleukin-17A inhibitor secukinumab than those with lower levels of the inflammatory marker, researchers report.

Golimumab may reduce uveitis risk in patients with ankylosing spondylitis

Findings from the real-world GO-EASY study suggest that treatment with the tumor necrosis factor inhibitor golimumab is associated with a significant reduction in the risk for acute anterior uveitis among patients with ankylosing spondylitis.

13-11-2018 | Ankylosing spondylitis | Highlight | News

Golimumab may reduce uveitis risk in patients with ankylosing spondylitis

Findings from the real-world GO-EASY study suggest that treatment with the tumor necrosis factor inhibitor golimumab is associated with a significant reduction in the risk for acute anterior uveitis among patients with ankylosing spondylitis.

03-10-2018 | Ankylosing spondylitis | Article

Influence of HLA-B27 on the ankylosing spondylitis phenotype: Results from the REGISPONSER database

Arévalo M et al. Arthritis Res Ther 2018; 20: 221. doi: 10.1186/s13075-018-1724-7

Further investigation of filgotinib warranted in ankylosing spondylitis patients

Findings from the phase II TORTUGA trial suggest that treatment with the JAK1 inhibitor filgotinib may be beneficial for patients with ankylosing spondylitis who have not responded to treatment with nonsteroidal anti-inflammatory drugs.

26-10-2018 | Ankylosing spondylitis | ACR/ARHP 2018 | News

Further evidence for the benefits of ixekizumab in ankylosing spondylitis

Findings from the COAST-W trial provide support for the IL-17A inhibitor ixekizumab as a treatment option for patients with ankylosing spondylitis and a previous inadequate response or intolerance to TNF inhibitor treatment.

26-10-2018 | Ankylosing spondylitis | News | Article

Further investigation of filgotinib warranted in ankylosing spondylitis patients

Findings from the phase II TORTUGA trial suggest that treatment with the JAK1 inhibitor filgotinib may be beneficial for patients with ankylosing spondylitis who have not responded to treatment with nonsteroidal anti-inflammatory drugs.

24-10-2018 | Ankylosing spondylitis | ACR/ARHP 2018 | News

Genetic risk scores may aid ankylosing spondylitis detection

Researchers have developed two polygenic risk scores to identify individuals at high risk for ankylosing spondylitis.

24-10-2018 | Cardiovascular disease | ACR/ARHP 2018 | Video

Looking to collaborative models of care to improve primary prevention of CVD in patients with inflammatory arthritis

Lihi Eder describes a new model of care based on collaboration between cardiologists and rheumatologists to better manage cardiovascular risk factors in patients with inflammatory arthritis (5:56).

COAST-V results support ixekizumab for the treatment of ankylosing spondylitis

Phase III trial results indicate that ixekizumab may be a promising treatment option for biologic-naïve patients with ankylosing spondylitis and an inadequate response or intolerance to nonsteroidal anti-inflammatory drugs.

23-10-2018 | Ankylosing spondylitis | ACR/ARHP 2018 | News

COAST-V results support ixekizumab for the treatment of ankylosing spondylitis

Phase III trial results indicate that ixekizumab may be a promising treatment option for biologic-naïve patients with ankylosing spondylitis and an inadequate response or intolerance to nonsteroidal anti-inflammatory drugs.

image credits